Navigation Links
Transave, Inc. Secures $12.5 Million in New Financing
Date:10/2/2008

ough nebulization since the small aerosol droplet size (~3.0 micrometers) facilitates lung distribution. Arikace has been granted orphan drug status in the United States by the FDA and has received an orphan drug designation in Europe by the European Medicines Agency (EMEA) for the treatment of Pseudomonas infections in patients with CF.

About Transave, Inc.

Transave, Inc. is a biopharmaceutical company focused on the development of innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases. The company's major focus is on developing inhaled antibiotic therapy delivered via next-generation liposomal technology in areas of high unmet need in respiratory disease. Transave is dedicated to leveraging its advanced liposomal development and commercialization expertise, along with its intellectual property, to bring life-extending and -enhancing medicines to patients. For more information about Transave's technology and development programs, visit http://www.transaveinc.com/.

About CIT

CIT (NYSE: CIT) is a global commercial finance company that provides financial products and advisory services to more than one million customers in over 50 countries across 30 industries. A leader in middle-market financing, CIT has more than $70 billion in managed assets and provides financial solutions for more than half of the Fortune 1000. A member of the S&P 500 and the Fortune 500, CIT maintains leading positions in asset-based, cash flow, and Small Business Administration lending, equipment leasing, vendor financing, and factoring. The CIT brand platform, Capital Redefined, articulates its value proposition of providing its customers with the relati
'/>"/>

SOURCE Transave, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing
2. Northwest Secures US$1.0 Million Debt Financing
3. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
4. Althea Technologies Secures $12 M Credit Line to Continue Facility Growth and Expansion
5. Progenitor Cell Therapy Secures Industry Accreditation
6. BIOCOM Institute Secures Non-Profit Designation and Funding
7. Cara Therapeutics Secures $12.3 Million in Series C Extension Financing
8. OMTEC 2008 Boasts Record Attendance and Secures Premier Position as Must-attend for Orthopaedic Companies
9. Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
10. Novasys Medical Secures $49.5 Million in Series D Financing to Expand Commercialization of Its Renessa(R) Treatment for Incontinence in Women
11. Veran Medical Technologies Secures $4.75M in First Institutional Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... -- Industry leaders from retail pharmacies ... the theme, ,Commercial Opportunities in the Era of Reform, ... Elsevier , a world-leading provider of scientific, technical ... gathering of some of the industry,s most prominent healthcare ... and in the future. The Elsevier Healthcare ...
(Date:9/30/2014)... a bio-mimicking analog of one of nature,s most ... research team led by Alejandro Briseno of the ... step in developing long-sought polymer architecture to boost ... in electronic devices. , Briseno, with colleagues ... at Stanford University and Dresden University of Technology, ...
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... to kill nematodes. Nematodes are microscopic parasitic roundworms, ... water, and inside other plants and animals. Nematicides ... volatility or other properties promoting migration through the ... more than 1,000 plant-parasitic nematodes. With more than ...
(Date:9/30/2014)... , Sept. 30, 2014  RegeneRx Biopharmaceuticals, Inc. ... that it has received a Canadian Patent for ... Peptides.  This patent includes claims using thymosin beta ... actin-sequestering peptides for these purposes.  The patent will ... Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
Breaking Biology Technology:Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... Jan. 31, 2012  Argos Therapeutics Inc., today announced ... analysis of AGS-003-006, a Phase 2 study of ... in patients with advanced renal cell carcinoma (RCC). ... anti-tumor memory T cell responses and overall survival. ...
... 2012   Veracyte, Inc ., a molecular diagnostics company ... the appointment of Mark Spring as chief financial officer. ... has joined the Veracyte team," said Bonnie Anderson, Veracyte,s ... a CFO and senior finance leader in both public ...
... Life Technologies Corporation (NASDAQ: LIFE ) ... the following upcoming investment conferences in February. ... present at the Leerink Swann 2012 Global Healthcare Conference ... Life Technologies will also present at the 2012 ...
Cached Biology Technology:Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC) 2Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC) 3Veracyte Appoints Mark Spring as Chief Financial Officer 2Veracyte Appoints Mark Spring as Chief Financial Officer 3Life Technologies to Present at Upcoming Investment Conferences in February 2
(Date:9/30/2014)... Fish can live in almost any aquatic environment on ... up many species are pushed to the limit. The ... could prove critical for how different species cope in ... the University of Gothenburg, published in the scientific journal ... Climate change continues apace thanks to increasing levels of ...
(Date:9/30/2014)... N.C. -- Pollution in urban and farm runoff in ... new study finds. , The study, published Tuesday ... that nitrogen in the runoff ends up in algae ... on the animals, eyes, flippers and internal organs. , ... the National Oceanic and Atmospheric Administration (NOAA) conducted the ...
(Date:9/30/2014)... (LMU) in Munich report that a new class ... to chemotherapeutic drugs. They have also pinpointed the ... for anti-tumor agents. , Researchers led by ... of the Technische Universitt Mnchen have identified a ... weapon in the fight against malignant tumors. The ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Cancer therapy: Driving cancer cells to suicide 2
... has been a well-kept secret of our immune system,s success. The ... Cell Press publication, offer an explanation for how specialized immune cells ... in the process. The focus of the study is a ... a pore in cells targeted for destruction. With that pore in ...
... uncovered a new role for a key cancer protein, a ... of a variety of tumors. Many cancers are driven ... the cells to escape growth controls and proliferate abnormally. In ... Nature , researchers discovered that cyclin D1 also helps ...
... Evidence from benchmark sites across the ... allows for land-use sharing in agriculture, forests and other ... gas emissions and raising food production levels. It provides ... land for forests through agricultural intensification. Agricultural intensification, also ...
Cached Biology News:How killer immune cells avoid killing themselves 2Cancer protein discovery may aid radiation therapy 2Cancer protein discovery may aid radiation therapy 3Integrating agriculture and forestry in the landscape is key to REDD 2
... between P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) ... the lumenal surface of endothelial cells at ... primary role of PSGL-1 in mediating the ... well documented.MAB4092 completely blocks recognition of PSGL-1 ...
Mitotic Kinesin-Like Protein 1 (MKLP-1, KNSL5)...
MMP-1/8 (H-300)...
... contains choice of Printing Surface (3 glass slides coated ... layer, 1 silicon wafer coated with 1000 Angstroms of ... slides) and PDMS Stamps (3 PDMS micropatterned stamps with ... um x 10 mm or 200 um x 10 ...
Biology Products: